Moss-made complement therapeutics
2018; Elsevier BV; Volume: 102; Linguagem: Inglês
10.1016/j.molimm.2018.06.203
ISSN1872-9142
AutoresAndreas Schaaf, Todor Tschogonov, Stefan Michelfelder, Nicola Krieghoff, Jonas P. Koch, Andreas Büsch, Paulina Dabrowska‐Schlepp, Lennard L. Bohlender, Juliana Parsons, Eva L. Decker, Ralf Reski, Karsten Häeffner, Thomas Frischmuth,
Tópico(s)Reproductive System and Pregnancy
ResumoHuman Leukocyte Antigen-G (HLA-G) is known as an immune suppressive molecule; it interacts with several immune cells and inhibits their functions. HLA-G molecule is highly represented in pathological conditions including malignant transformation. To the best of our knowledge this is the first study that focuses on the expression of soluble HLA-G (sHLA-G) in endometrial cancer (EC). We aimed at exploring sHLA-G plasma levels and its prognostic value in EC.We examined total sHLA-G expression as well as the sHLA-G1 and HLA-G5 isoforms expression in plasma samples from 40 patients with EC and 45 healthy controls by a specific sandwich ELISA. Immunoprecipitation and Coomassie blue staining were performed to explore the presence of plasmatic sHLA-G monomers and dimers.sHLA-G plasma level was significantly enhanced in patients with EC compared to healthy controls (p = 0.028). Additionally, HLA-G5 molecules were highly represented than sHLA-G1 molecules in EC, at the borderline of significance (p = 0.061). Interestingly, sHLA-G has been shown to be increased in early stages (Stages I and II) as well as in high grade EC (Grade 3) that is associated with rapid spread of the disease (p = 0.057). sHLA-G positive EC plasma were majorly in monomeric form (75%). Clinically, all the HLA-G dimers were detected in early stages and in high grade of EC.Our data strengthen the implication of HLA-G molecules in EC etiology and especially in progression.
Referência(s)